Autologous dendritic cell vaccine (ADCV) in combination with plasmapheresis (PP) and cyclophosphamide (Cy) in patients with disseminated melanoma: A phase II study.

WT1-targeted dendritic cell vaccination as a postremission treatment to prevent or delay relapse in acute myeloid leukemia.

The final report of a phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with glioblastoma.

Correlation of survival with tumor antigen expression in patients with newly diagnosed glioblastoma receiving a multi-epitope pulsed dendritic cell vaccine.

CD40 ligand/interferon-γ matured DC immunization with gp100 antigen HLA class I  A *0201 restricted peptides in patients with newly diagnosed metastatic melanoma.

Adjuvant dendritic cell (DC)-based vaccine therapy of melanoma patients.

Allogeneic partially HLA-matched dendritic cells (DC) as a vaccine in metastatic renal cell cancer (mRCC): Final analysis of a clinical phase I/II study.

[Dendritic cell-based therapeutic vaccination for acute myeloid leukemia]